You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Andrea Anderson covers genomics research studies and translational research for GenomeWeb. Find her on Twitter at @andyandy_tk.
Interim results from a study in the Netherlands suggest whole-genome sequencing can be done fast enough to uncover treatment targets in metastatic cancer patients.
Patients with discordant p16 and HPV markers fall into an intermediate risk group, research presented at the European cancer conference suggests.
Breast cancer risk in carriers of pathogenic CHEK2 variants may be classified as low, moderate, or high by adding in polygenic risk score and family history data.
Data presented at ACMG's online annual meeting suggests that more than 10 percent of prostate cancer patients across disease stages carry inherited cancer-related variants.
A single-cell "atlas" of pathologically normal breast tissue was presented by an MD Anderson Cancer Center representative at the AACR's online annual meeting this week.
By tapping into available population sequence and single-cell RNA sequence data, researchers are attempting to understand SARS-CoV-2 susceptibility.
Researchers have been using Nextstrain, which includes data for thousands of SARS-CoV-2 genomes, to study how the virus accrues mutations over time.
Drawing from its massive consumer genetic dataset and longitudinal survey data, 23andMe is searching for genetic features that might influence the severity of SARS-CoV-2 infections.
Investigators worldwide are sharing data to search for features in the human genome that might contribute to COVID-19 susceptibility or progression.
Nearly 3,500 patients were referred to the Roberts Individualized Medical Genetics Center for exome sequencing or other testing during the clinical program's first four years.
The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.
The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.
Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.
In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.